It could happen...Glaxo Smith Kline (GSK) is very pleased with the Relenza sales given the latest flu season in North America and would be quite interested in the latest lab tests which show Relenza's ability to inhibit the H5N1 avian flu strain. These results were publicised all over the world.
It would be in their interest to control Biota's research and receive the positive publicity from breakthoughs.
The takeover price, assuming A$1.00 per share, would only be approx A$100 mil...close to the minimum valuation required to get a Nasdaq listing!
Add to My Watchlist
What is My Watchlist?